QI
BMY.RT

QS Investors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

QS Investors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-17,126
Closed -$12K – 1269
2020
Q4 		$12K Hold
17,126
– – ﹤0.01% 1168
2020
Q3 		$39K Hold
17,126
– – ﹤0.01% 1155
2020
Q2 		$62K Hold
17,126
– – ﹤0.01% 1425
2020
Q1 		$66K Hold
17,126
– – ﹤0.01% 1358
2019
Q4 		$55K Buy
+17,126
New +$44.5K ﹤0.01% 1455

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

QS Investors's BMY.RT Position: Q1 2021 in Review

QS Investors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 17,126 shares — an estimated $12K sold.

QS Investors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $66K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • QS Investors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • QS Investors sold 17,126 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $12K.
  • QS Investors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • QS Investors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $66K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on QS Investors's 13F filing for Q1 2021, filed 13 May 2021.